Healthcare
Unicycive Therapeutics, Inc.(UNCY)
Live Price
Offline$6.85
-2.84% today
1Y Change
+2.25%
Window
Jun 23, 2025 โ Jun 9, 2026
- Market Cap
- $160.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +70.2%
- Dividend Yield
- 0.0%
Coverage: 242 bars ยท Jun 23, 2025 โ Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Unicycive Therapeutics, Inc. (UNCY) is a Healthcare stock with a market cap of $160.00M and listed on NASDAQ. The stock last traded around $6.85 and up 2.3% across the available one-year price window (Jun 23, 2025 โ Jun 9, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +70.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +70.2%, free cash flow -9.4% with operating margin 0.0% and ROIC -97.4%. Stock Foundry combines UNCY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on May 12, 2026 with an EPS surprise of -17.7%.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +70.2%, while operating margin sits near 0.0%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 13, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.8% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | -17.7% | +4.2% | -5.4% | โ |
2026 Mar 30, 2026 | +36.6% | +7.7% | +9.3% | +17.3% |
2025 Nov 12, 2025 | +33.9% | +3.7% | +7.6% | +24.7% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
UNCY
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
UNCY Max Drawdown
-47.40%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for UNCY and SPY.
Company Overview
Unicycive Therapeutics, Inc.
NASDAQ Capital Market
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
- Leadership
- Shalabh K. Gupta
- IPO Date
- Jul 12, 2021
- Employees
- 22
- Street Address
- 4300 El Camino Real
- Mailing
- Los Altos, CA, 94022
- Region
- Los Altos, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 351 4495
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 40.4
Growth
- Revenue
- 0.0%
- EPS
- +70.2%
- Free Cash Flow
- -9.4%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -111.4%
- ROIC
- -97.4%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 2.59
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.